Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 4, 2000, Pages 293-304

  Lu, K ^a   Shih, C ^a   Teicher, B A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cyclin cdk; Cyclins; pRB

Indexed keywords

ACTIN; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLINE; DP 1 PROTEIN; FLAVOPIRIDOL; GENISTEIN; OLOMOUCINE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER RESISTANCE; CELL CYCLE; CELL SURVIVAL; COLON CARCINOMA; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; TUMOR XENOGRAFT;

EID: 0033770781     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000136     Document Type: Article

References (70)

1. Genistein, a specific inhibitor of tyrosine-specific protein kinases
2. Cyclin D1 protein is over expressed in hyperplasia and intraductal carcinoma of the breast
3. Regulation of CDK/cyclin complexes during the cell cycle
4. Cyclin D1 in breast cancer
5. The retinoblastoma protein pathway in cell cycle control and cancer
6. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
7. The current status of tyrosine kinase inhibitors: Do the diarylamine inhibitors of the EGF receptor represent a new beginning?
8. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells
9. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells
10. Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells
11. Chemical inhibitors of cyclin-dependent kinases
12. The cell cycle and cancer
13. Genistein inactivates bcl-2, delays the G2/M phase of the cell cycle, and induces apoptosis of human breast adenocarcinoma MCF-7 cells
14. Antitumoral activity of flavone L 86-8275
15. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with roscovitine
16. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma
17. CDKs and cyclins in transition(s)
18. Genistein, a dietary-derived inhibitor of in vitro angiogenesis
19. L-Dopa decarboxylase activity (DDC): A distinguishing biomarker for the growth of small cell lung cancer (SCLC) in tissue culture
20. Effects of dibutyral cyclic adenosine 3',5'-monophosphate on the growth of cultured human small cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase
21. CDK inhibition and cancer therapy
22. Threshold expression of cyclin E but not D type cyclins characterizes normal and tumor cells entering S phase
23. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors
24. Cyclin dependent kinase inhibitors
25. pRB plays an essential role in cell cycle arrest induced by DNA damage
26. The retinoblastoma protein: A master regulator of cell cycle, differentiation and apoptosis
27. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo
28. Cyclins and cancer. II. Cyclin d and CDK inhibitors come of age
29. Effects of cyclin D1 overexpression on G1 progression-related events
30. The expanding role of cell cycle regulators
31. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases in rat liver
32. Unscheduled expression of cyclins D1 and D3 in human tumor cell lines
33. Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic
34. Functional consequences of cyclin D1 overexpression in human mammary luminal epithelial cells
35. Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas
36. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas
37. Expression of cyclin D1, CDK4 and p27 kip1 is associated with the p16MTS1 gene status in human esophageal carcinoma cell lines
38. Purification, characterization and kinetic mechanism of cyclin D1, CDK4, a major target for cell cycle regulation
39. Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma
40. The cell cycle in breast cancer
41. Cyclin D1 overexpression and prognosis in colorectal adeno-carcinoma
42. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer
43. Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas
44. Roscovitine induces cell death and morphological change indicative of apoptosis in MDA-MB-231 breast cancer cells
45. A transgenic mouse model with cyclin D1 overexpression results in cell cycle, epidermal growth factor receptor and p53 abnormalities
46. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach
47. Effect of genistein on topoisomerase activity and on the growth of [Val12]Ha-ras-transformed NIH 3T3 cells
48. An important role for the retinoblastoma protein in staurosporine-induced G1 arrest in murine embryonic fibroblasts
49. Expression of cyclin D1 and retinoblastoma protein in colorectal cancer
50. A restriction point for control of normal animal cell proliferation
51. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell carcinoma
52. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-β
53. Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities
54. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells
55. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas
56. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
57. Role of the retinoblastoma protein in the pathogenesis of human cancer
58. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
59. Cell kinetics
60. Mammalian G1 cyclins
61. Cyclins and breast cancer
62. Cyclin D1 overexpression detected by a simple competitive reverse transcription-polymerase chain reaction assay for lymphoid malignancies
63. Calmodulin is essential for cyclin-dependent kinase 4 (Cdk4) activity and nuclear accumulation of cyclin D1-Cdk4 during G1
64. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity
65. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination
66. CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons
67. Tumor suppressor genes
68. The retinoblastoma protein and cell cycle control
69. RB protein status and chemosensitivity in non-small cell lung cancers
70. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma